BHDP - Scottish Cancer Registry (SMR06)

Preview of JSON file

{
  "linkage": {
    "associatedMedia": "https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/overview/what-is-edris/"
  },
  "summary": {
    "title": "BHDP - Scottish Cancer Registry (SMR06)",
    "abstract": "Public Health Scotland is responsible for the collection of information on Scottish residents when they are diagnosed with malignant (and some benign) tumours.\n\nThis is a subset of data for the Brain Health Data Pilot (BHDP)",
    "keywords": "Cancer;,;BHDP;,;Brain Health",
    "publisher": {
      "name": "Public Health Scotland",
      "gatewayId": "c40be7ce-f0ca-4fd8-b63c-0632593d2507"
    },
    "inPipeline": "Not available",
    "shortTitle": "BHDP - Scottish Cancer Registry (SMR06)",
    "datasetType": "Health and disease",
    "description": "The Brain Health Data Pilot (BHDP) project aims to be a shared database (like a library) of information for scientists studying brain health, especially for diseases like dementia, which affects about 900,000 people in the UK. Its main feature is a huge collection of brain images linked to routinely collected health records, both from NHS Scotland, which will help scientists learn more about dementia and other brain diseases. What is special about this database is that it will get better over time – as scientists use it and add their discoveries, it becomes more valuable. \n\nThis is a subset of the Scottish Cancer Registry (SMR06) dataset for use in the Brain Health Data Pilot (BHDP) project. \n\nThe registry began in 1958 collecting personal, demographic and diagnosis information (such as site, histology, behaviour, histological confirmation and hospital of diagnosis) from cancer patients. In 1997, a new electronic cancer recording system was launched and at this point the registry was extended to include extra information on tumour stage (for breast, cervical and colorectal cancer), tumour grade and treatment information. A wide variety of geographical data is also included in the dataset including Scottish Index of Multiple Deprivation and Carstairs measures, census output area, NHS Board, Electoral Ward and Parliamentary constituency.",
    "contactPoint": "phs.edris@phs.scot",
    "datasetSubType": "Not applicable",
    "populationSize": 219396
  },
  "coverage": {
    "spatial": "United Kingdom,Scotland",
    "followUp": "Other",
    "typicalAgeRange": "0-150"
  },
  "required": {
    "issued": "2024-10-08T11:28:17.973532Z",
    "version": "1.0.0",
    "modified": "2024-10-08T11:28:17.973545Z",
    "gatewayId": "66",
    "revisions": [
      {
        "url": "https://web.prod.hdruk.cloud//dataset/66?version=1.0.0",
        "version": "1.0.0"
      }
    ],
    "gatewayPid": "488ab019-d42c-4b1a-9aae-414cd635d88a"
  },
  "provenance": {
    "origin": {
      "source": "EPR",
      "purpose": "Care",
      "imageContrast": "Not stated",
      "collectionSituation": "Clinic;,;Primary care - Clinic;,;Secondary care - Outpatients;,;Secondary care - In-patients"
    },
    "temporal": {
      "endDate": "2024-05-09",
      "timeLag": "Not applicable",
      "startDate": "2001-01-01",
      "accrualPeriodicity": "Static",
      "distributionReleaseDate": "2024-06-17"
    }
  },
  "observations": [
    {
      "observedNode": "Persons",
      "measuredValue": 219396,
      "observationDate": "2024-05-09",
      "measuredProperty": "count",
      "disambiguatingDescription": "People in dataset"
    },
    {
      "observedNode": "Events",
      "measuredValue": 290452,
      "observationDate": "2024-05-09",
      "measuredProperty": "Count",
      "disambiguatingDescription": "Number of Records"
    }
  ],
  "accessibility": {
    "usage": {
      "resourceCreator": {
        "name": "National Services Scotland;,;Public Health Scotland"
      },
      "dataUseLimitation": "Research-specific restrictions",
      "dataUseRequirement": "Collaboration required;,;Geographical restrictions;,;Institution-specific restrictions;,;Not for profit use"
    },
    "access": {
      "accessRights": "https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/services-we-offer/",
      "jurisdiction": "GB-GBN",
      "accessService": "Scottish National Safe Haven / Trusted Research Environment: https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/national-safe-haven-nsh/\n\nBrain Health Data Pilot Study",
      "dataProcessor": "National Services Scotland",
      "dataController": "Public Health Scotland",
      "deliveryLeadTime": "Not applicable",
      "accessRequestCost": "https://publichealthscotland.scot/services/data-research-and-innovation-services/electronic-data-research-and-innovation-service-edris/cost-of-services/"
    },
    "formatAndStandards": {
      "formats": "text/csv",
      "languages": "en",
      "vocabularyEncodingSchemes": "NHS SCOTLAND NATIONAL CODES"
    }
  },
  "structuralMetadata": [
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Scottish Incidence Date",
          "dataType": "8",
          "sensitive": false,
          "description": "Scottish Incidence date is the date that the cancer in question becomes formally known to NHS \nScotland. Previously known as ‘date treatment commenced’ and/or ‘Incidence Date’. Can be termed \n“date of diagnosis” \n(A) For patients seen as outpatients and/or day cases and/or inpatients (other than long stay or residential), it is the earliest available date from the following: - Date of first consultation as an outpatient.             - Date of first pathology report confirming diagnosis - Date of admission to hospital.                                \n- Date of hospital-initiated treatment \nIf none of the above dates apply or can be established, the date of diagnosis (or best estimate) should be used. \n(B)\tFor long stay or residential patients, or patients receiving care at home, it is the date of diagnosis (or best estimate). \n(C)\tFor death certificate only cases (when follow-up attempts have been unsuccessful), and for cases first diagnosed at autopsy (unsuspected during life), it is the date of death."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Side (Laterality)",
          "dataType": "1",
          "sensitive": false,
          "description": "This indicates the side or laterality of origin (i.e. left or right) in the case of paired organs.  (e.g. breast, kidney, limb, lung, ovary, testis). Acceptable SIDE is based on the current UKACR table of Laterality. Tumours existing in both sides of a paired organ should be registered twice for Left and Right. The only paired organs to be treated as a single site (bilateral) are tumours of the ovary and Wilms tumour of the kidney or nephroblastoma. (ICDO(3) 8960/3) Options: \nCode \tDescription \n0 \tNot applicable (non paired organs) \n1 \tRight \n2 \tLeft \n3 \tBilateral \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "Source Data",
      "columns": [
        {
          "name": "ICD-10 Conv. Site",
          "dataType": "6",
          "sensitive": false,
          "description": "Converted to ICD-10 code from SNOMED and ICD-9 codes"
        }
      ],
      "description": "Source Data"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Tumour Site – ICDO(2) / ICDO(3) Code",
          "dataType": "6",
          "sensitive": false,
          "description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Similar to ICD10 site code, but there are differences in the site code ranges. ICDO(2) does not include type specific codes such as lymphomas (C82-C85) or Kaposi’s sarcoma (C46), but has the ability to code such neoplasms more precisely to their site of origin. All registrations should now be completed with an ICDO(2) site code, regardless of incidence. This field is collected for all registrations with a Scottish incidence date from 1.1.1997.  With the introduction of ICDO(3), it should be noted that there is no change in the codes for SITE from ICDO(2) to ICDO(3)."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Tumour Type - ICDO Code",
          "dataType": "6",
          "sensitive": false,
          "description": "ICDO - International Classification of Diseases for Oncology. Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICD-O morphology code and a fifth digit which denotes behaviour of the tumour.  \nAll registrations with a Scottish incidence date up to and including 31.12.1996 should be classified according to the ICDO classification.   \n5th digit options: \n \nCode \tDescription \n0 \tBenign \n1 \tUncertain whether benign or malignant   \n2 \tCarcinoma in situ \n3 \tMalignant- primary site \n6 \tMalignant- metastatic site or secondary site \n9 \tMalignant- uncertain whether primary or metastatic site"
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Tumour Type - ICDO(2) Code",
          "dataType": "6",
          "sensitive": false,
          "description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(2) morphology code and a fifth digit which denotes behaviour. All registrations with a Scottish incidence date from 1.1.1997 to 31.12.2005 should now be completed with an ICD(O)2 morphology code. There are some differences between ICDO and ICDO(2) including the change in behaviour of certain tumour types from one classification to the other."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Tumour Type - ICDO(3) Code",
          "dataType": "6",
          "sensitive": false,
          "description": "ICDO(3) - International Classification of Diseases for Oncology (3rd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(3) morphology code and a fifth digit which denotes behaviour. \n5th digit options: \n \nCode \tDescription \n0 \tBenign \n1 \tUncertain whether benign or malignant \n2 \tCarcinoma in situ \n3 \tMalignant- primary site \n6 \tMalignant- metastatic site or secondary site \n9 \tMalignant- uncertain whether primary or metastatic site \nPlease note there are some differences between ICDO(2) and  ICDO(3) including the change in behaviour of certain tumour types from one classification to the other. This field will be completed for all registrations with a Scottish incidence date from 1.1.2006. Registrations with a Scottish incidence date from 1.1.2012 onwards, will adopt the 2011 updated version of codes for ICDO3."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Grade Classification Used",
          "dataType": "1",
          "sensitive": false,
          "description": "Indicates the classification system used for grading tumour.  Options: \n \nCode \tDescription \n1 \tGrading for breast cancer (ICD10 C50 and D05). \n2 \tICD-O/UICC \n3 \tGleason Score (Prostate only – ICD10 C61)   \n4 \tBloom and Richardson (Breast only) *NOW OBSOLETE* \n5 \tFuhrman nuclear grade/ISUP (VANCOUVER) (Renal cell carcinomas of kidney – ICD10 C64 \n6 \tWHO grade (Brain and CNS only -  ICD10 C70-C72, D32 – D33, D35.2 – D35.4, D42 – D43, D44.3 – D44.5 \n7 \tGIST only C15*, C16*, C17*, C18*, C20*, C25*, C269, C48.1, C762, C80* and morphology 89363 \n8 \tOther \n9 \tNot determined/not stated/not applicable \n \nFor code 1 note: \nThe Nottingham grading system (previously option 1) and the Bloom and Richardson grading system (previously option 4) have been combined, as one is essentially a modification of the other. The new Grading for breast cancer (option 1) will be used from the introduction in October 2010 of the newly developed Socrates version and should be completed for all cases of breast cancer. Option 4 is now obsolete. All previously registered cases of Bloom and Richardson Grade have been electronically amended to record the new option 1.  \n \nFor code 5 note: \nFuhrman nuclear grade was introduced as an option in Socrates in 2006. Previously, this classification was recorded under [8] Other. ISUP (VANCOUVER) was introduced as an option in Socrates in 2014. \n \nFor code 6 note: \nThis was previously recorded under [8] Other with a note of grade in the Admin screen. To be collected for records from 1.1.2006 Scottish incidence onwards. \nFor code 7 note: \nThis was introduced for 2016 registrations. \n For most other cancers, the ICD-O/UICC grading system is used. If the grade of differentiation is explicitly enumerated in the pathology report it should be recorded as such. If it is not explicitly stated, it may be derived from the text of the pathology report according to the definition options stated for Grade below. Grade is recorded every time this information is available except when T or B cell origin is provided for lymphomas & leukaemias. In this event, the T or B - cell origin has priority and also has options stated in Grade definition below.  \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Grade or Cell type",
          "dataType": "2",
          "sensitive": false,
          "description": "Grade or cell type indicates the degree of differentiation of malignant tumours or the T-cell & B-cell designation for lymphomas and leukaemias and is sometimes recorded as the sixth digit of the ICDO morphology code, although this is not recorded on SOCRATES. \n \nBreast options:  \nCode \tDescription \n1 \tGrade 1 / low grade   \n2 \tGrade 2 / intermediate grade   \n3 \tGrade 3 / high grade   \n9 \tNot Known \n \nProstate -‘Gleason Score’ Options: 2 -10 or 0 (Not known).  \nUp to Scottish incidence date 31.12. 2010, the Gleason score will be recorded as the sum of the \nGleason Major score and Gleason Minor score. From 1.1.2011 Scottish incidence date onwards, the Grade or Cell type field will contain the Gleason Major, Minor and Tertiary score separately. Options: 1 - 5 or 9 (Not known).  \nTo be completed for all prostate cases with an ICD10 code of C61. \n\nKidney – ‘Fuhrman’/ISUP (VANCOUVER) Options: \nCode \tDescription \n1 \tGrade I \n2 \tGrade II \n3 \tGrade III \n4 \tGrade IV \n9 \tNot Known \n \nWHO (Brain and CNS) Options:  \nCode \tDescription \n1 \tGrade I \n2 \tGrade II \n3 \tGrade III \n4 \tGrade IV \n9 \tNot Known \n \n \n \n \nGIST (sarcoma GIST tumours only) Options: \nCode \tDescription \nGX \tGrade cannot be assessed \nG1 \tLow grade; mitotic rate 5/50 per high-power field (HPF) or less \nG2 \tHigh grade; mitotic rate > 5/50 HPF \n \nICD-O/UICC Options:  \n\tCode \tDescription \n\t1 \t(Well) differentiated   \n\t2 \tModerately (well) differentiated \n\t3 \tPoorly differentiated   \n\t4 \tUndifferentiated, anaplastic \n\t5 \tT-Cell (inc. T-precursor)  \n\t6 \tB-Cell (inc. Pre-B, B-precursor) \n\t7 \tNull Cell ( Non T-non B, leukaemias only) \n\t8 \tNatural killer (NK) Cell   \n\t9 \tGrade/Cell type or differentiation not determined, not stated or not applicable. \n\nTo be used for all diagnostic sites other than those above. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Most Valid Basis of Diagnosis",
          "dataType": "1",
          "sensitive": false,
          "description": "Most Valid Basis of diagnosis indicates the method judged to have best provided or validated the diagnosis during the course of the illness.  Options: \nCode \tDescription \n1 \tClinical only \n2 \tClinical investigation (including x-ray, ultrasound, etc.) \n3 \tExploratory surgery/endoscopy/autopsy  (without concurrent or previous histology) \n4 \tSpecific biochemical and/or immunological tests (e.g. Prostate Specific Antigen (PSA) - for prostate cancer or Bence Jones Protein (BJP) - for Myeloma) \n5 \tCytology (including blood film or bone marrow aspirate) \n6 \tHistology of metastasis \n7 \tHistology of primary \n8 \tAutopsy (with concurrent or previous histology) \n9 \tNot Known \n10 \tDeath certificate only   \n \nThe methods of diagnosis are listed in essentially ascending order of validity, microscopic methods having greater validity than non-microscopic methods. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Histological \nVerification",
          "dataType": "1",
          "sensitive": false,
          "description": "Histological Verification is microscopic confirmation of the histological or cytological diagnosis (including examination of peripheral blood film). For post-97 registrations, HV-verified should correspond with Most Valid Basis Of Diagnosis options 5-8.  \nNOTE - CIN 3 should only be registered if the diagnosis is based on histology, not cytology alone.  Options: \n \nCode \tDescription \n1 \tVerified \n2 \tNot verified\n9 \tNot Known"
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "DIAGNOSIS DETAILS",
      "columns": [
        {
          "name": "Method of First Detection",
          "dataType": "1",
          "sensitive": false,
          "description": "Method of first detection indicates how the tumour was first detected. \n \nOptions: \nCode \tDescription \n1 \tScreening examination \n2 \tIncidental finding (on examination or at surgery for an unrelated reason) \n3 \tClinical presentation (with relevant symptoms) \n4 \tIncidental finding at autopsy (previously unsuspected) \n5 \tInterval cancer \n8 \tOther \n9 \tNot Known \n \nInterval cancer is an option introduced in the redeveloped SOCRATES in 2006. It describes when a primary tumour with histological confirmation is diagnosed in the interval following a negative screening episode and before the next scheduled screening examination.  The \"interval\" relates to the interval between screenings rather than the interval between separate tumour occurrences. \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997."
        }
      ],
      "description": "DIAGNOSIS DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_CLINICAL_T",
          "dataType": "2",
          "sensitive": false,
          "description": "Clinical stage indicates the extent of spread of the tumour at diagnosis in terms of clinical findings.\nStage is associated with invasive tumours only.\nT-size/ Extent of Primary tumour based on clinical examination ± imaging, e.g. mammography."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_CLINICAL_N",
          "dataType": "2",
          "sensitive": false,
          "description": "Condition of regional lymph nodes/glands based on clinical examination ± imaging"
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_CLINICAL_M",
          "dataType": "2",
          "sensitive": false,
          "description": "Indicates distant metastases."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_PATHOLOGIC_T",
          "dataType": "2",
          "sensitive": false,
          "description": "Pathological Stage indicates the extent of the spread of the tumour at diagnosis in terms of the pathological findings.\nBreast and lung will be collected from incidence 01/01/2005. Renal and prostate will be collected from 01/01/2013\nStage is associated with invasive tumours only.\nT-size/ Extent of Primary tumour based on clinical examination ± imaging, e.g. mammography."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_PATHOLOGIC_N",
          "dataType": "2",
          "sensitive": false,
          "description": "Condition of regional lymph nodes/glands based on clinical examination ± imaging"
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_PATHOLOGIC_M",
          "dataType": "2",
          "sensitive": false,
          "description": "Indicates distant metastases."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "Clinical extent of disease",
          "dataType": "1",
          "sensitive": false,
          "description": "Options: \nCode \tDescription \n1 \tLocalised \n2 \tRegional spread    \n3 \tDistant metastasis   \n4 \tNot Known \n \nThis field will be collected for all malignant lung tumours (C34*) registered with a Scottish incidence date from 1.1.2005 to 31.12.2012"
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_COLORECTAL",
          "dataType": "2",
          "sensitive": false,
          "description": "Stage (Colorectal) indicates the extent of spread of the invasive tumour at diagnosis in terms of the pathological and/or clinical findings for Socrates. Extent of Primary tumour for Colorectal cancer - \nDukes’ staging is primarily based on histological findings.  Dukes’ Staging Classification Options: \n \nCode \tDescription \nA \tTumour limited to muscularis propria (muscle coat), regional lymph nodes negative \nB \tTumour invades through muscularis propria into serosa/subserosa or through peritoneum but regional lymph nodes negative \nC1 \tRegional lymph nodes positive but apical node negative \nC2 \tRegional lymph nodes positive, apical lymph node positive \nD \tDistant metastases (e.g. liver) \n9 \tNot Known \nNote: Dukes’ stage D was not included in the original Dukes’ classification \nNote:  Regional lymph nodes are the pericolic and perirectal and those located along the ileocolic, right colic, middle colic, left colic, inferior mesenteric and superior rectal (haemorrhoidal) arteries \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997 onwards for all malignant colorectal (ICD10 C18 – C20) and anal (ICD10 C21) tumours."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_FIGO_AFTER_SURGERY",
          "dataType": "3",
          "sensitive": false,
          "description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for Cervix and ovary at diagnosis in terms of the pathological and/or clinical findings.\nFrom 01/01/1997  FIGO stage will be collected for invasive tumours of the cervix. From 01/01/2005 incidence date FIGO stage will also be collected for invasive tumours of the ovary."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "STAGE DETAILS",
      "columns": [
        {
          "name": "STAGE_FIGO_BEFORE_SURGERY",
          "dataType": "3",
          "sensitive": false,
          "description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for Cervix and ovary at diagnosis in terms of the pathological and/or clinical findings. FIGO stage will be collected for all tumours of the cervix and ovary from an incidence date of 01/01/2005."
        }
      ],
      "description": "STAGE DETAILS (Tumour Level)"
    },
    {
      "name": "Scottish Index of Multiple Deprivation (SIMD)",
      "columns": [
        {
          "name": "SIMD Scotland Quintile",
          "dataType": "INTEGER",
          "sensitive": false,
          "description": "Format\nInteger\n\nField Length\n1\n\nPriority\nLocal\n\nDefinition\nA categorisation which divides the Scottish population into five equal categories based on the range of SIMD scores so that 20% of the population falls into each quintile (population weighted).\n\nPoints to note\n\nFor SIMD2016\nMost Deprived Quintile = 1\nLeast Deprived Quintile = 5"
        }
      ],
      "description": "The index is an area based measure, calculated at data zone level and has seven domains (income, employment, education, housing, health, crime and geographical access). These have been combined into an overall index. Please note that SIMD values may appear for records prior to 1999, however ISD recommendations are to use SIMD for trend analyses from 1999 onwards. For trend analyses back to 1991, use the 2001 census based Carstairs deprivation.\nFor trend analyses back to before 1991, use the 1991 census based Carstairs deprivation. See the ISD website for further information.\nPlease indicate which SIMD version you would like for each selected variable.\n \nNote on change in ordering of quintiles and deciles\nFollowing the release of the SIMD 2009, ISD changed their ordering of quintiles and deciles to fit with the method that is used by the Scottish Government\n(SG). For SIMD 2009, SIMD 2012 and future releases, the method is now: 1 = MOST deprived, 5 or 10 = LEAST deprived\n \n ISD analyses based on SIMD 2006 or SIMD 2004 will be left in their current format:  1 = LEAST deprived; 5 or 10 = MOST deprived.\nTo avoid confusion, deprivation categories should always be fully labelled. For example, for SIMD 2012, 'decile 1 (most deprived)'… 'decile 10 (least deprived)'.\nFor time trend analyses combining SIMD 2004/2006 with SIMD 2009/2012 it is important to treat all deciles and quintiles in the same way. SIMD 2004/2006 deciles/quintiles should be reversed from 1=LEAST deprived, 5 or 10=MOST deprived to 1=MOST deprived, 5 or 10=LEAST deprived in order to keep the same convention for the deciles and quintiles throughout the analysis."
    }
  ]
}